SEC Form 4 · accession 0001209191-16-094820
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqualyn A Fouse
Officer — see remarks
Period of report
Feb 1, 2016
Accepted (ET)
Feb 2, 2016 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $100.80 | Feb 1, 2016 | A | 8,625 | A | — | Feb 1, 2026 | Common Stock | 8,625 | 8,625 | D |
Explanation of responses
- F1Option is immediately exercisable and will vest in four equal annual installments commencing on February 1, 2017.
- F2The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as Amended and Restated as of April 15, 2015).
Remarks
President Hematology and Oncology